Very good_老虎社区_美港股上老虎

GeoLegends
2021-08-27

Very good

This Warren Buffett Dividend Stock Is Still Dirt Cheap

The Oracle of Omaha has already made a great return from his investment in this big pharma stock.

This Warren Buffett Dividend Stock Is Still Dirt Cheap

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":819518073,"tweetId":"819518073","gmtCreate":1630076748492,"gmtModify":1704955667854,"author":{"id":3584748254057781,"idStr":"3584748254057781","authorId":3584748254057781,"authorIdStr":"3584748254057781","name":"GeoLegends","avatar":"https://static.tigerbbs.com/9b58fc6a4f5903eabaf4a377779a7a2f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Very good</p></body></html>","htmlText":"<html><head></head><body><p>Very good</p></body></html>","text":"Very good","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/819518073","repostId":2162427042,"repostType":4,"repost":{"id":"2162427042","kind":"highlight","pubTimestamp":1630067420,"share":"https://www.laohu8.com/m/news/2162427042?lang=&edition=full","pubTime":"2021-08-27 20:30","market":"us","language":"en","title":"This Warren Buffett Dividend Stock Is Still Dirt Cheap","url":"https://stock-news.laohu8.com/highlight/detail?id=2162427042","media":"Motley Fool","summary":"The Oracle of Omaha has already made a great return from his investment in this big pharma stock.","content":"<p>Warren Buffett might not be as much of a value investor as he once was. However, he still likes to get a good bargain for the stocks added to <b>Berkshire Hathaway</b>'s (NYSE:BRK.A) (NYSE:BRK.B) holdings.</p>\n<p>The legendary investor also seems to prefer dividend stocks -- even though Berkshire itself has never paid a dividend. Most of the stocks Berkshire owns offer dividends.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> dividend stock in Berkshire's portfolio that especially looks attractive right now. <b>AbbVie</b> (NYSE:ABBV) is a Dividend Aristocrat with 49 consecutive years of dividend increases. Its dividend yield currently stands north of 4.3%. And even better, this Buffett dividend stock is still dirt cheap.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/807dfaa86ede0364962d9f0316ccdb99\" tg-width=\"700\" tg-height=\"511\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Buffett's bargain</h2>\n<p>Berkshire first scooped up shares of AbbVie in the third quarter of 2020. The big pharma stock traded on average at close to nine times expected earnings during the period. By comparison, Berkshire's own shares traded at a forward earnings multiple of more than 25 throughout most of the third quarter last year.</p>\n<p>We don't know exactly when Berkshire first bought AbbVie stock during Q3 of 2020. If purchases were made at the peak price during the quarter, Berkshire is now sitting on a gain of close to 20%. However, if the transactions were completed near the low price for AbbVie during the period, Berkshire's gain is more than 40%. No matter how you look at it, Buffett found a bargain.</p>\n<p>Even with the big gains, though, AbbVie's valuation remains attractive. The stock currently trades at 9.6 times expected earnings. The forward earnings multiple for the <b>S&amp;P 500</b> index is just under 21. Healthcare stocks in the S&amp;P 500 trade on average at 17.6 times expected earnings. The average forward earnings multiple for pharmaceutical stocks stands at 15.</p>\n<h2>Behind AbbVie's low valuation</h2>\n<p>Why is AbbVie stock so cheap? There are two main reasons.</p>\n<p>Most importantly, AbbVie's crown jewel will soon lose its luster. Humira has been its top-selling drug since the company was spun off from <b>Abbott</b>&nbsp;in 2013. The autoimmune disease drug has even reigned for several years as the best-selling drug in the world.</p>\n<p>However, Humira will face biosimilar rivals in the U.S. market beginning in 2023. Its sales will almost certainly plunge. Biosimilars are already on the market in Europe. As a result, Humira's international sales have fallen from $6.25 billion in 2018 to $3.7 billion in 2020. A similar sales decline in the U.S. will be a big blow for AbbVie, since Humira generated more than 36% of its total revenue in the company's latest quarter.</p>\n<p>The second key reason behind AbbVie's low valuation is related to the impending challenges for Humira. AbbVie believes that it can largely offset the lower sales for Humira with its other products. But the company must secure regulatory approvals for new indications for several drugs that are already on the market to achieve this goal. AbbVie faces risks that it won't be able to pick up the needed regulatory wins.</p>\n<p>For example, the U.S. Food and Drug Administration (FDA) has delayed its approval decisions for Rinvoq in treating psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis. The drug has already been approved by the FDA for treating rheumatoid arthritis. However, AbbVie's hopes to make up for declining sales of Humira could be dashed if Rinvoq fails to gain these additional approvals.</p>\n<h2>Reasons for optimism</h2>\n<p>AbbVie President Mike Severino said in the Q2 conference call in July that the company remains confident that Rinvoq will win approvals in the three indications for which the FDA has delayed decisions. He noted that the FDA hasn't requested any additional safety data, which could be interpreted as a positive sign.</p>\n<p>The European Commission recently approved Rinvoq in treating atopic dermatitis. The drug has already won European approvals as a treatment for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.</p>\n<p>AbbVie isn't solely dependent on Rinvoq, though. The company has great expectations for another autoimmune disease drug, Skyrizi. It also looks for antipsychotic drug Vraylar to generate peak sales of close to $4 billion and for its two migraine drugs, Ubrelvy and atogepant, to each achieve peak sales of over $1 billion. Several other current blockbusters should also enjoy continued momentum, notably including blood cancer drugs Imbruvica and Venclexta.</p>\n<p>The big drugmaker projects that it will quickly bounce back from lower overall sales in 2023 when biosimilars to Humira enter the U.S. market. Over the second half of this decade, AbbVie expects strong revenue growth. With those prospects combined with a great dividend, Buffett's investment in AbbVie seems likely to pay off in an even bigger way over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Warren Buffett Dividend Stock Is Still Dirt Cheap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Warren Buffett Dividend Stock Is Still Dirt Cheap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/27/this-warren-buffett-dividend-stock-is-still-dirt-c/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett might not be as much of a value investor as he once was. However, he still likes to get a good bargain for the stocks added to Berkshire Hathaway's (NYSE:BRK.A) (NYSE:BRK.B) holdings.\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/27/this-warren-buffett-dividend-stock-is-still-dirt-c/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","ABBV":"艾伯维公司","BRK.B":"伯克希尔B"},"source_url":"https://www.fool.com/investing/2021/08/27/this-warren-buffett-dividend-stock-is-still-dirt-c/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162427042","content_text":"Warren Buffett might not be as much of a value investor as he once was. However, he still likes to get a good bargain for the stocks added to Berkshire Hathaway's (NYSE:BRK.A) (NYSE:BRK.B) holdings.\nThe legendary investor also seems to prefer dividend stocks -- even though Berkshire itself has never paid a dividend. Most of the stocks Berkshire owns offer dividends.\nThere's one dividend stock in Berkshire's portfolio that especially looks attractive right now. AbbVie (NYSE:ABBV) is a Dividend Aristocrat with 49 consecutive years of dividend increases. Its dividend yield currently stands north of 4.3%. And even better, this Buffett dividend stock is still dirt cheap.\nImage source: Getty Images.\nBuffett's bargain\nBerkshire first scooped up shares of AbbVie in the third quarter of 2020. The big pharma stock traded on average at close to nine times expected earnings during the period. By comparison, Berkshire's own shares traded at a forward earnings multiple of more than 25 throughout most of the third quarter last year.\nWe don't know exactly when Berkshire first bought AbbVie stock during Q3 of 2020. If purchases were made at the peak price during the quarter, Berkshire is now sitting on a gain of close to 20%. However, if the transactions were completed near the low price for AbbVie during the period, Berkshire's gain is more than 40%. No matter how you look at it, Buffett found a bargain.\nEven with the big gains, though, AbbVie's valuation remains attractive. The stock currently trades at 9.6 times expected earnings. The forward earnings multiple for the S&P 500 index is just under 21. Healthcare stocks in the S&P 500 trade on average at 17.6 times expected earnings. The average forward earnings multiple for pharmaceutical stocks stands at 15.\nBehind AbbVie's low valuation\nWhy is AbbVie stock so cheap? There are two main reasons.\nMost importantly, AbbVie's crown jewel will soon lose its luster. Humira has been its top-selling drug since the company was spun off from Abbott in 2013. The autoimmune disease drug has even reigned for several years as the best-selling drug in the world.\nHowever, Humira will face biosimilar rivals in the U.S. market beginning in 2023. Its sales will almost certainly plunge. Biosimilars are already on the market in Europe. As a result, Humira's international sales have fallen from $6.25 billion in 2018 to $3.7 billion in 2020. A similar sales decline in the U.S. will be a big blow for AbbVie, since Humira generated more than 36% of its total revenue in the company's latest quarter.\nThe second key reason behind AbbVie's low valuation is related to the impending challenges for Humira. AbbVie believes that it can largely offset the lower sales for Humira with its other products. But the company must secure regulatory approvals for new indications for several drugs that are already on the market to achieve this goal. AbbVie faces risks that it won't be able to pick up the needed regulatory wins.\nFor example, the U.S. Food and Drug Administration (FDA) has delayed its approval decisions for Rinvoq in treating psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis. The drug has already been approved by the FDA for treating rheumatoid arthritis. However, AbbVie's hopes to make up for declining sales of Humira could be dashed if Rinvoq fails to gain these additional approvals.\nReasons for optimism\nAbbVie President Mike Severino said in the Q2 conference call in July that the company remains confident that Rinvoq will win approvals in the three indications for which the FDA has delayed decisions. He noted that the FDA hasn't requested any additional safety data, which could be interpreted as a positive sign.\nThe European Commission recently approved Rinvoq in treating atopic dermatitis. The drug has already won European approvals as a treatment for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\nAbbVie isn't solely dependent on Rinvoq, though. The company has great expectations for another autoimmune disease drug, Skyrizi. It also looks for antipsychotic drug Vraylar to generate peak sales of close to $4 billion and for its two migraine drugs, Ubrelvy and atogepant, to each achieve peak sales of over $1 billion. Several other current blockbusters should also enjoy continued momentum, notably including blood cancer drugs Imbruvica and Venclexta.\nThe big drugmaker projects that it will quickly bounce back from lower overall sales in 2023 when biosimilars to Humira enter the U.S. market. Over the second half of this decade, AbbVie expects strong revenue growth. With those prospects combined with a great dividend, Buffett's investment in AbbVie seems likely to pay off in an even bigger way over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":387,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}